Custom knee implant maker ConforMIS has priced the latest major med tech IPO with its $135 million offering on July 1. Investor appetite for large med tech IPOs raising more than $100 million remains whetted, despite the encroachment of the summer doldrums that can slow Wall Street activity to a crawl.
Med techs are looking to revive public market interest. Several IPOs priced during the first few months of the year--but there's been a lull lately. Custom joint replacement maker ConforMIS is readying an IPO to raise up to $172.5 million, while gastrointestinal endoscopy player EndoChoice has set terms to raise $100 million. Also, Palo Alto, CA-based, breast tissue expansion company AirXpander is starting an IPO to raise A$36.5 million (US $28.3 million) on the Australian Securities Exchange.
Orthopedic implant maker ConforMIS disclosed that it has expanded--and come close to doubling--its Series E financing to a whopping $167.7 million.
These are dubious times for medical device companies seeking venture investment.
ConforMIS successfully raised $73 million through the sale of stock and convertible securities on Wednesday. The fundraising, noted in a new regulatory filing, is a bit of a coup, in fact, surpassing an initially-announced plan to pull in $68 million through the action.
ConforMIS, which makes orthopedics implants, plans to raise $68 million in an equity and securities funding round, according to a recent regulatory filing.
ConforMIS will use $89 million in newly raised investor financing to fuel the commercial launch and manufacturing of its new iTotal total knee replacement system. The Burlington, MA-based company
ConforMIS has secured a $1.4 million loan from MassDevelopment's Emerging Technology Fund. The loan will go toward growing the Burlington, MA-based company's supply chain and manufacturing capacity
ConforMIS said today that the first surgeries involving the iTotal CR knee resurfacing system were successfully completed in hospitals around the U.S. And, according to a company release, the